Amytrx Therapeutic's AMTX-100 CF3 moves to phase II clinical trial for atopic dermatitis

Amarex Clinical Research guides its client to phase II of FDA trials

Marinus expands enrollment criteria to support recruitment in Phase 3 RAISE Trial in refractory status epilepticus

Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.

Olema Oncology and Aurigene collaboration to discover and develop novel cancer therapies

During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.

GE Healthcare’s molecular imaging solutions enable precision health & theranostics for prostate cancer

Healthcare is timely and personal – and its delivery should be too

Bayer’s Vividion emerging as significant player in San Diego Biotech hub

Bayer now present in four of the largest biotechnology hubs in the United States

Sumitomo Pharma Oncology receives orphan drug designation for the treatment of myelofibrosis

TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.

Merck and Ridgeback announce new data for investigational molnupiravir

Based on a post hoc analysis, fewer required respiratory interventions

Halozyme announces commercial launch of testosterone undecanoate 'TLANDO'

TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.

Lonza launches new non-endotoxin pyrogen detection system

The human serum-based system shows reduced interferences when testing for pyrogenicity in more complex drug products, such as in blood-derived therapeutics

Ovensa and Celanese to collaborate to advance precision drug delivery